丹麦制药巨头Novo Nordisk开发的新型注射式肥胖症药物amycretin在早期试验中展现出超越当前市场主导产品的减重潜力,为该公司在与礼来公司的激烈竞争中提供了新的希望。 据《柳叶刀》医学期刊周六发布的试验数据,接受amycretin注射剂最高剂量治疗的参与者平均减重24.3%,而安慰剂组仅减重1.1%。这一结果超过了目前市场上最成功的减重药物——礼来的Zepbound(平均减重22.5%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.